ARS Pharmaceuticals, Inc. Common Stock
Here’s whether ARS Pharmaceuticals, Inc. Common Stock (SPRY) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: RSI 39 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-2.39% over 10 days); weak 1-year return of -45.3%; 3-month momentum negative (-13.1%); rising volume on a downtrend (distribution, 1.16x avg). Currently 58.0% off its 52-week high. Score: -5/7.
SPRY is trading below its 200-day MA ($9.86) — a key warning sign the longer-term trend is under pressure. An RSI of 38.8 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -45.3% compares to +27.9% for SPY (trailed the market by 73.2%). The current 58.0% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.